O	0	1	A
O	2	7	pilot
O	8	18	randomized
O	19	27	clinical
O	28	33	study
O	34	36	of
O	37	40	the
O	41	49	additive
O	50	59	treatment
O	60	66	effect
O	67	69	of
B-intervention	70	82	photodynamic
I-intervention	83	90	therapy
O	91	93	in
O	94	100	breast
O	101	107	cancer
O	108	116	patients
O	117	121	with
O	122	127	chest
O	128	132	wall
O	133	143	recurrence
O	143	144	.

O	145	149	This
O	150	155	study
O	156	168	investigated
O	169	172	the
O	173	181	additive
O	182	188	effect
O	189	191	of
O	192	204	photodynamic
O	205	212	therapy
O	213	214	(
O	214	217	PDT
O	217	218	)
O	219	223	plus
O	224	235	traditional
O	236	248	radiotherapy
O	249	250	(
O	250	252	RT
O	252	253	)
O	254	257	for
O	258	266	patients
O	267	271	with
O	272	278	breast
O	279	285	cancer
O	286	289	and
O	290	295	chest
O	296	300	wall
O	301	311	recurrence
O	311	312	.

O	313	314	A
O	315	320	total
O	321	323	of
B-total-participants	324	326	40
B-eligibility	327	335	patients
I-eligibility	336	340	with
I-eligibility	341	350	recurrent
I-eligibility	351	357	breast
I-eligibility	358	364	cancer
O	365	369	were
O	370	383	prospectively
O	384	394	randomized
O	395	397	to
O	398	405	receive
B-control	406	408	RT
I-control	409	414	alone
O	415	416	(
O	416	421	group
O	422	423	A
O	423	424	,
O	425	426	n
O	426	427	=
B-control-participants	427	429	20
O	429	430	)
O	431	433	or
O	434	437	PDT
O	438	441	and
O	442	444	RT
O	445	447	in
O	448	459	combination
O	460	461	(
O	461	466	group
O	467	468	B
O	468	469	,
O	470	471	n
O	471	472	=
B-intervention-participants	472	474	20
O	474	475	)
O	475	476	.

O	477	488	Traditional
O	489	491	RT
O	492	494	at
O	495	496	a
O	497	501	dose
O	502	504	of
O	505	507	50
O	508	510	Gy
O	511	514	was
O	515	524	delivered
O	525	527	in
O	528	530	25
O	531	540	fractions
O	541	545	with
O	546	548	or
O	549	556	without
O	557	565	exposure
O	566	568	to
O	569	570	5
O	570	571	-
O	571	585	aminolevulinic
O	586	590	acid
O	591	594	and
O	595	598	red
O	599	604	light
O	605	607	as
O	608	611	PDT
O	611	612	.

O	613	616	The
B-outcome	617	625	response
I-outcome	626	631	rates
O	632	636	were
O	637	640	not
O	641	654	statistically
O	655	664	different
O	665	672	between
O	673	676	the
O	677	683	groups
O	683	684	,
O	685	688	but
O	689	693	more
O	694	702	patients
O	703	711	achieved
O	712	713	a
O	714	722	complete
O	723	731	response
O	732	733	(
O	733	735	CR
O	735	736	)
O	737	739	in
O	740	745	group
O	746	747	B
O	748	749	(
B-iv-bin-percent	749	751	50
I-iv-bin-percent	751	752	%
O	752	753	)
O	754	758	than
O	759	761	in
O	762	767	group
O	768	769	A
O	770	771	(
B-cv-bin-percent	771	773	20
I-cv-bin-percent	773	774	%
O	774	775	)
O	775	776	.

O	777	780	The
B-outcome	781	787	median
I-outcome	788	792	time
I-outcome	793	795	to
I-outcome	796	798	CR
O	799	801	in
O	802	807	group
O	808	809	B
O	810	813	was
O	814	827	significantly
O	828	835	shorter
O	836	840	than
O	841	845	that
O	846	848	in
O	849	854	group
O	855	856	A
O	857	858	(
B-iv-cont-median	858	861	109
I-iv-cont-median	861	862	.
I-iv-cont-median	862	863	6
I-iv-cont-median	864	868	days
O	869	871	vs
O	871	872	.
B-cv-cont-median	873	876	175
I-cv-cont-median	876	877	.
I-cv-cont-median	877	878	2
I-cv-cont-median	879	883	days
O	883	884	,
O	885	886	p
O	886	887	=
O	887	888	0
O	888	889	.
O	889	892	001
O	892	893	)
O	893	894	.

B-outcome	895	902	Adverse
I-outcome	903	908	event
I-outcome	909	917	profiles
O	918	922	were
O	923	926	not
O	927	936	different
O	937	944	between
O	945	948	the
O	949	955	groups
O	955	956	.

O	957	959	An
O	960	968	additive
O	969	978	antitumor
O	979	985	effect
O	986	988	is
O	989	1001	demonstrated
O	1002	1006	with
O	1007	1017	additional
O	1018	1021	PDT
O	1022	1024	to
O	1025	1027	RT
O	1027	1028	.

O	1029	1033	This
O	1034	1045	combination
O	1046	1053	therapy
O	1054	1059	might
O	1060	1066	reduce
O	1067	1070	the
O	1071	1079	duration
O	1080	1082	of
O	1083	1091	exposure
O	1092	1094	to
O	1095	1097	RT
O	1097	1098	,
O	1099	1102	but
O	1103	1110	further
O	1111	1124	investigation
O	1125	1127	is
O	1128	1137	warranted
O	1137	1138	.
